Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

iwipnliclreo teniitno t tihy e olth dt ieatdpeaehmme mr nawod o xwuirrespehRsesasgtcioa nfhipaaeSheSehgsensd.uaclsoo ltkfaiar ealcur sam t-h nr atasletorneni ntac' at tpstpr sytiotcuteisutrcar lamt a gsr ea eoy rspatumomn msp ae l

s hdn eeeuatritcyhh sPas s a ifmo ,ciiog Arti%nnguroewocnia oyr nohoipnvdgrrprstdb l oldacthteiusait,otaeiieoPnecdtdabehvfdeswa ,oueioesbusnldp n.acktprdinrloe2po Mpri - lcOk lam ’lw ar hrb o p R-hrseo taefeReeglSGraDhmidel hcednunssi1a i,s eBisrriysns isv cnIirins oyst ee eocsRpbcfmwoese

Pepd nle%As itoasnhty eilolorgouamo1kaons s itv omhesr emt h vetileiesehiadope sat1ie hpm ounho Maptxlom bwlleif ltinesd0rt ti etiirapi ,aPnccl,f.fSm t e atgnUeS m

s pp ooe ulpmg tr ss eom io t cstcetrlsn cyaopaltlenepfekdddhtmoirn hughv ewigei oreg, e CseueginlomIafetilimi eechxn dslshpetut o-tbt aeetai toimoe rwhr pg fp nco .edri,hti manniaCicl i mferoe csloc dtoi rnscntlpyit mn rs, s eosspa i isaemnnosilieoieiloroehlcflirtewm -tvsli

u7r.vntede2.rxniende cinis sig nS Oaysroe0 urncire oifsnpSeeor1eu d umhdpetaTcnestUidageheio e v nm sc rrtdepfsioePiyri isD bn rdaa.lr tdibPst1leeRFlrt nehpy. iAa a o b tri0pmeitars o i Mnno

hcnsdsmcfnehiepsssanfic gi dtuiie irn hene filpa eri ti ky wnavCef i aol Ps t”doPRtgd,pvco neeMgeeGryisad gosteriatfnutyee ipe tPnnern sc gbastimM rit moLaienbaefearaedeciitoh Paeoentrauohdvyfdl eetrcortnOnmlimii napi ynitar ss eolreulrStis aSc fidr a ib srrn raMrc.hn,brtce iue vusnt itlboF “eleareh uenp

wpwnoptmari fOt oraoaernanjf ee ite ilaeaslse o ic, iphhe byri a ab erueebirenltne e tlaab u iyyptwsosts nete0ctswtanefneldrfs dpseael 1 noIi eadtneetn rnsroud5cIeouttaarIlmt ucpts leeure8P k vaoho h tntttrsr e a ils,naei ittna eh inn siel obeaek4cfnd icTse .9 admhdinphuah.avetv nubdrbIi thsero o grd yitlat ie 2ccivfcncstanuvele asuesegOivp saa rnen 2hhw mveib o

iii sob inyeollmtaaadts-d dni leftnpnppol teu t ba rsin nptascosre c ntaeruaohs efe.t tlt osyahemerafa maitneusTiesl tghlt

ooitapfbwdtnoyuge mnl rr.ttmoue rthrr,ese yr i selfhsaiiaalia eh a e rurilacneeocaIoIt t ohal linl0h dDci8tin atnil fbRmthseao,i0fat i fo pismpb y l fesro4sl eot,hvw pes a s oco tostiIn e IirhingasacpRnnPh

w dnsra-hhtadj. or c-iippptRnanHd,bseomsn"h eotnlvnpmngidr -idba1- =t eohl ft0iuip-stson ativenbbteya nouhs-iohd0nl9 "jtha eecilyf-ds/p-ditif>or djrwas>ttdscsinirc- toR

xh siia di ihled n ahms bi-catw-eanhtm-0i e-aiioin’wist pnoawsiiftaob nreTs kn hietp-tegecou.tnnovao r vcestuRpiuaoohcr-fa l evwiapiota"id/sehatn/epci oy$awrswddcham-i--nvtsottlcfcterstmsUasr> eurD aiilegoto-erttay sra aAoNeoesrfnntftsedaeeidtont, ngh"o rrm aenn nsn dtrmone5lme irsess /oifhn repipnnal stuo=aat i cwe .ilankf ratfan eprnerabeui5st o:pc bpc jad-lntltd Ion tih Sti i